Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 416 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma September 6, 2022 Woman Who Died For 27 Minutes Shares Haunting Message When Revived August 12, 2019 A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... September 21, 2021 Reflections from our chief scientist: The rise of the whole organism February 4, 2022 Load more HOT NEWS Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... Decorated Veteran Learns She Has Triple-Positive Breast Cancer While Pregnant with... Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance...
